Shares of diagnostic company Exact Sciences Corporation (NASDAQ:EXAS) fell 5.9% in the morning session after the company reported underwhelming fourth-quarter 2024 results as profit margins worsened ...

Acquisition adds a new growth vertical to Abbott's already high single-digit growth profile, gaining leadership in the fast-growing $60 billion U.S. cancer screening and precision oncology diagnostics ...

Abbott announced Thursday morning that it is acquiring Exact Sciences for $21 billion. The deal values Exact Sciences at $105 per share, representing a 22% premium to the cancer screening company’s ...

The business is unprofitable, but it has been growing at an impressive rate in recent years. And there's still more growth on the horizon for the business. Here's what I expect from the company over ...

Abbott's acquisition of Exact Sciences aims to improve cancer diagnostics and expand access to early detection and management. Exact Sciences' products, including Cologuard and Oncotype DX, will ...

The healthcare conglomerate Abbott Laboratories said on Thursday it would buy Exact Sciences, makers of the at-home colon cancer test Cologuard, for roughly $21 billion. The deal appears to be the ...

Exact Sciences has moved to acquire Genomic Health, with plans to bring their cancer screening and diagnostic tests up through a combined commercial organization of about 1,000 employees, including ...

Exact Sciences’ (NDAQ: EXAS) history is a tale of two halves. Founded in 1995 in Marlborough, Massachusetts, “Exact,” as the company is known, went public in 2001 but struggled to find its footing, ...

The rumors are now a reality. Abbott Laboratories is acquiring Exact Sciences for $21 billion, marking what could be the biggest medtech deal of 2025. The deal’s announcement comes less than 24 hours ...

Exact Sciences is adding early cancer detection to its pipeline through its buyout of Thrive Earlier Detection for up to $2.15 billion in cash and stock. The deal comes just three months after Thrive ...